Skip to main content
OpenTrials
Completed

NCT Number: NCT00997139

Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment

Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasal Carriers of Staphylococcus Aureus Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Staphylococcal Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northwestern University

Chicago, Illinois, 60611, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to give informed consent
  • Must have consented prior to registration for the study

Exclusion criteria

  • active infection
  • concurrent treatment with antibiotics, topical or systemic
  • S. aureus decolonization attempt in prior six months
  • history of HIV
  • chemotherapy or systemic immunosuppressive therapy
  • history of neomycin allergy or sensitivity

Treatment and study plan

Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)

Drug

2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.

Primary outcomes

  1. Carrier Rate for Staphylococcus Aureus

    Time frame: Baseline

    Percentage of subjects with baseline culture positive for Staphylococcus aureus (via nasal swab)

  2. MSSA Clearance Rate

    Time frame: 14 days

    Percentage of subjects with methicillin-sensitive S. aureus on Baseline culture who achieved clearance with treatment.

  3. MRSA Clearance Rate

    Time frame: 14 days

    Percentage of subjects with methicillin-resistant S. aureus on Baseline culture who achieved clearance with treatment.

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Registry information

Official study title

Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Oct 19, 2009
Registry last updated
Jan 5, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.